← Oncology Approval Tracker

FDA DECISION ·

Romidepsin injection

romidepsin · Teva Pharmaceuticals USA

Accelerated approvalNew formulationPeripheral T-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Dec 8, 2021

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with peripheral T-cell lymphoma who had received at least one prior therapy.

LAMPGEN ANALYSIS

Why it matters

The liquid injection formulation carried accelerated approval for this peripheral lymphoma indication, which FDA later withdrew.

What research teams should watch

Keep the historical peripheral lymphoma action distinct from the cutaneous lymphoma indication for the same product.

PRIMARY RECORDS

Sources